marco newsbot

Uncovering BioTwitter's best links on a single page

Last updated Today, 12:05 am

sort Top links

Thumbnail
Fairfax County Public Schools:
  • schools had to agree they would "not in the next twelve (12) months purchase any products that are competitive to EpiPen(R) Auto-Injectors," ...
Herbert Hovenkamp:
  • "It is illegal to issue a discount on the condition the customer not acquire a competitor’s goods — if the effect may be to substantially lessen competition," said Herbert Hovenkamp ...
John Torre:
  • Torre said that the district is "closely monitoring the Mylan situation" and "actively exploring alternative vendors to meet our needs for the annual supply of epinephrine."
Harry First:
  • "It’s like the bank robber saying ‘Don’t worry, we don’t rob banks anymore,’" First said. "But if you make such a change, it casts doubt on why you needed to have such a requirement in the first place."

Mylan may have violated antitrust law in its EpiPen sales to schools

STAT  — by Ed Silverman, Ike Swetlitz  Yesterday, 11:25 am

Schools across the country keep EpiPens in their nurses' offices in case a student has a severe allergic reaction. For years, Mylan Pharmaceuticals has been selling the devices to schools at a discounted price, giving them a break from rising costs.

Thumbnail

Stealthy Biotech Revives Stalled Parkinson's Drug, Reveals Plans In Alzheimer's and ALS

Forbes  — by Matthew Herper  Yesterday, 12:17 pm

Denali CEO Ryan Watts Denali Therapeutics, the stealthy South San Francisco biotech startup that raised $217 million last year to fight Alzheimer's, Parkinson's, and ALS, is finally lifting the curtain on its plans this morning. It is also announcing that it has raised another $130 million from investors in a private [...]

Thumbnail
Heather Bresch:
  • "We have been a long-term, committed partner to the allergy community and are taking immediate action to help ensure that everyone who needs an EpiPen Auto-Injector gets one," Bresch said in the statement. "Patients deserve increased price transparency and affordable care, particularly as the system shifts significant costs to them."
  • Bresch asking her to "provide a briefing to Committee staff on the pricing of EpiPen at a mutually convenient time no later than two weeks from today." ...
Mylan NV:
  • Mylan NV said it would take immediate action to cut the cost of its EpiPen emergency allergy shot following pressure from politicians including presidential candidate Hillary Clinton, who called past price increases "outrageous" ...

Mylan to Reduce EpiPen Costs as Political Pressure Mounts

Bloomberg  — by Anna Edney, Kristen Hallam  Yesterday, 11:29 am

Mylan NV said it would take immediate action to cut the cost of its EpiPen emergency allergy shot following pressure from politicians including presidential candidate Hillary Clinton.

Thumbnail

Amgen's Shameful Silence Covers Up Reasons for FDA Drug Rejection

TheStreet  — by Adam Feuerstein  Yesterday, 1:32 pm

An Amgen ( AMGN) drug to treat secondary hyperparathyroidism was rejected by U.S. regulators on Wednesday, but in an egregious abdication of corporate transparency, the biotech company offered no public explanation at all for why the drug's marketing application was denied.

Thumbnail

This Princeton health economist thinks Obamacare's marketplaces are doomed

Vox  — by Sarah Kliff  Yesterday, 12:30 pm

I've spent the past week talking to lots of health care experts and economists about the future of the Affordable Care Act. Of all the people I spoke with, Princeton University health economist Uwe Reinhardt offered the most dire and pessimistic assessment of the marketplaces' future.

Thumbnail

Mylan Boosts Assistance for EpiPen After Pricing Backlash

WSJ  — by Austen Hufford  Yesterday, 11:58 am

Mylan NV responded Thursday to backlash over price increases for its EpiPen emergency allergy treatment by promising to reduce the costs that some patients pay, though the drugmaker stopped short of saying it would roll back prices or limit future increases.

Thumbnail
Genzyme:
  • Genzyme began in 1981 as a startup with a handful of employees in an old clothing warehouse on the edge of what was then known as the "Combat Zone" ...

5 top blunders of life science startups

STAT  — by Laurie Halloran  Yesterday, 12:46 pm

Hundreds of biotech companies spring to life each year in pursuit of the same basic goal: to make it big. Some succeed. Genzyme began in 1981 as a startup with a handful of employees in an old clothing warehouse on the edge of what was then known as the "Combat Zone" - Boston's red light district.

Thumbnail

How to Get the Cheaper EpiPen Alternative

Consumer Reports  Wednesday, 9:22 pm

Consumer Reports shares what you need to know to get a cheaper EpiPen alternative.

Thumbnail

Mylan Taking Immediate Action to Further Enhance Access to EpiPen® (Epinephrine Injection, USP) Auto-Injector

AbbVie Newsroom  Yesterday, 11:12 am

HERTFORDSHIRE, England and PITTSBURGH, Aug. 25, 2016 / PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced it is taking immediate action to further enhance access to EpiPen(epinephrine injection, USP) Auto-Injector by expanding already existing programs in recognition of those patients who are facing the burden of higher out-of-pocket costs.

Thumbnail

Empirical assessment of published effect sizes and power in the recent cognitive neuroscience and psychology literature

bioRxiv  — by John Ioannidis, Denes Szucs  Yesterday, 9:33 pm

We have empirically assessed the distribution of published effect sizes and estimated power by extracting more than 100,000 statistical records from about 10,000 cognitive neuroscience and psychology papers published during the past 5 years. The reported median effect size was d=0.93 (inter-quartile range: 0.64-1.46) for nominally statistically significant results and d=0.24 (0.11-0.42) for non-significant results.

Marco is the ENDPOINTS newsbot, constantly exploring the biopharma social web. These stories are discovered and ranked by algorithm, lightly edited by Shehla Shakoor.


Hot Hot this week

1
Pfizer nears $14bn takeover of Medivation
Financial Times   08/21/2016 9:35 pm
2
Fairfax County Public Schools:
  • schools had to agree they would "not in the next twelve (12) months purchase any products that are competitive to EpiPen(R) Auto-Injectors," ...
Herbert Hovenkamp:
  • "It is illegal to issue a discount on the condition the customer not acquire a competitor’s goods — if the effect may be to substantially lessen competition," said Herbert Hovenkamp ...
John Torre:
  • Torre said that the district is "closely monitoring the Mylan situation" and "actively exploring alternative vendors to meet our needs for the annual supply of epinephrine."
Harry First:
  • "It’s like the bank robber saying ‘Don’t worry, we don’t rob banks anymore,’" First said. "But if you make such a change, it casts doubt on why you needed to have such a requirement in the first place."
Mylan may have violated antitrust law in its EpiPen sales to schools
STAT   Yesterday, 11:25 am